Next Article in Journal
Economic Impact of New Active Substance Status on EU Payers’ Budgets: Example of Dimethyl Fumarate (Tecfidera®) for Multiple Sclerosis
Previous Article in Journal
The Value of Quantitative Patient Preferences in Regulatory Benefit-Risk Assessment
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 2
Issue 1
10.3402/jmahp.v2.25925
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Letter

Pricing and Reimbursement of Novel Oncology Drugs in Sweden

by
Mattias Haglund
1,* and
Eric Miller
2
1
IIB Partner AB, Stockholm, Sweden
2
Optio Biopharma SolutionsLLC, USA
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2014, 2(1), 25925; https://doi.org/10.3402/jmahp.v2.25925
Submission received: 1 January 2014 / Revised: 1 January 2014 / Accepted: 1 January 2014 / Published: 9 December 2014

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

We read with great interest the article by Cohen and Felix (1) concerning reimbursement restrictions on orphan drugs [...]

Share and Cite

MDPI and ACS Style

Haglund, M.; Miller, E. Pricing and Reimbursement of Novel Oncology Drugs in Sweden. J. Mark. Access Health Policy 2014, 2, 25925. https://doi.org/10.3402/jmahp.v2.25925

AMA Style

Haglund M, Miller E. Pricing and Reimbursement of Novel Oncology Drugs in Sweden. Journal of Market Access & Health Policy. 2014; 2(1):25925. https://doi.org/10.3402/jmahp.v2.25925

Chicago/Turabian Style

Haglund, Mattias, and Eric Miller. 2014. "Pricing and Reimbursement of Novel Oncology Drugs in Sweden" Journal of Market Access & Health Policy 2, no. 1: 25925. https://doi.org/10.3402/jmahp.v2.25925

APA Style

Haglund, M., & Miller, E. (2014). Pricing and Reimbursement of Novel Oncology Drugs in Sweden. Journal of Market Access & Health Policy, 2(1), 25925. https://doi.org/10.3402/jmahp.v2.25925

Article Metrics

Back to TopTop